Table 1

Basic characteristics of patients receiving OAT from 2013 to 2017 in Norway

Basic characteristicsTotal20132014201520162017
Individuals>1 OAT10 37177097914795878047709
Deaths692165151138114124
Gender, n (%)
 Male7135 (69)5221 (69)5390 (69)5430 (69)5354 (70)5254 (69)
 Female3236 (31)2323 (31)2373 (31)2390 (31)2336 (30)2340 (31)
Age, n (%)
 <25211 (3)185 (2)171 (3)135 (2)120 (2)
 26–402813 (37)2797 (36)2718 (40)2574 (33)2432 (32)
 41–604289 (57)4537 (58)3644 (53)4627 (60)4613 (61)
 >60231 (3)244 (3)287 (4)354 (5)420 (6)
OAT medication, n (%)
 Methadone/levomethadone3406 (45)3264 (42)3216 (41)3066 (40)2981 (39)
 Buprenorphine based*4138 (55)4499 (58)4604 (59)4624 (60)4604 (61)
 Dispensions of HCV drugs†1475146167243322597
OAT continuity category, n (%)
 I: ≥2 DDD5310 (51)
 II: 1–2 DDD3078 (30)
 III: <1 DDD1983 (19)
  • *Buprenorphine and buprenorphine/naloxone.

  • †HCV drugs: interferon-based and DAAs.

  • DDDs, Daily defined Doses; HCV, hepatitis C virus; NorPD, Norwegian prescription database; OAT, opioid agonist therapy.